Abcellera Biologics Inc

+0.07 (1.71%)
NASDAQ (CLOSED)

Abcellera Biologics Inc (ABCL) @ NASDAQ

Printed Tuesday, 19 May '26 00:42 MST
Abcellera Biologics Inc

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Biotechnology Common Stock β +1.027

Website Attributes Seasonality Filters
Date Name (*Public) Description Symbol Type Size Action
Date Value Error Logarithmic Error Model (*Public)
+$0.07 (1.71%) on Monday, 18 May 2026, Marketcap $1.27 B
Date Value Δ Open Close Low High Adjusted Volume Δ
Name Version (*Public) Indicator % Auto Description Symbol Company Name Forecasts Buy / Sell Action
Opened (Closed) Expires Symbol Company Name Name (*Public) Size Contract Symbol Open P/L Close P/L Total P/L ROI DTE DIT Delta Action
Details Best Trend by Hindsight Forecast Profit or Loss
Date (*Public) Symbol Strategy Data Origin Slope Sigma Cor % Moves Sigma Moves Gain % Periods Action
Date Name (*Public) Description Price Quantity Total Cost Type Symbol Action
Date RSI Stochastic %D Stochastic %K MACD MACD Divergence MACD Signal DMI CCI Volatility Bollinger Upper Bollinger Mid Bollinger Lower
Date Name Description Type Symbol Company Name Location
Date UTC Location Action Description Object Severity User Action